Evidence map›Paper›PMID 29491759›Full record

ArticleGastroenterology & hepatology2018

Hepatitis B Virus Infection and Organ Transplantation.

Walid S Ayoub, Paul Martin, Kalyan Ram Bhamidimarri

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Gastroenterology & hepatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Walid S AyoubDr Ayoub is a clinical associate professor of medicine in the Department of Digestive and Liver Diseases and an assistant medical director of the Liver Transplant Program at Cedars-Sinai Medical Center in Los Angeles, California. Dr Martin is a professor of medicine and Dr Bhamidimarri is an associate professor of medicine in the Division of Gastroenterology and Hepatology at the University of Miami Miller School of Medicine in Miami, Florida.
Paul MartinDr Ayoub is a clinical associate professor of medicine in the Department of Digestive and Liver Diseases and an assistant medical director of the Liver Transplant Program at Cedars-Sinai Medical Center in Los Angeles, California. Dr Martin is a professor of medicine and Dr Bhamidimarri is an associate professor of medicine in the Division of Gastroenterology and Hepatology at the University of Miami Miller School of Medicine in Miami, Florida.
Kalyan Ram BhamidimarriDr Ayoub is a clinical associate professor of medicine in the Department of Digestive and Liver Diseases and an assistant medical director of the Liver Transplant Program at Cedars-Sinai Medical Center in Los Angeles, California. Dr Martin is a professor of medicine and Dr Bhamidimarri is an associate professor of medicine in the Division of Gastroenterology and Hepatology at the University of Miami Miller School of Medicine in Miami, Florida.
University of Miami · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis B virus (HBV) infection remains an important cause of liver disease and continues to present several unique challenges in organ transplantation despite the availability of an effective vaccine to prevent HBV infection and the introduction of oral therapy to treat HBV infection over 20 years ago. HBV recurrence following liver transplantation can now be prevented with antiviral therapy, although controversy persists as to whether immunoprophylaxis with hepatitis B immunoglobulin is also necessary. HBV reactivation following organ transplantation can occur even in recipients with absent hepatitis B surface antigen at the time of transplantation and remains an important cause of morbidity and mortality. Expansion of the donor pool by using organs from hepatitis B core antibody-positive donors can result in HBV infection in the recipient. Another challenge is severe HBV reactivation leading to liver failure in HBV-infected patients receiving immunomodulatory agents, which are increasingly being used for a variety of nonneoplastic indications.

Indexed as

hepatitis B core antibodyhepatitis B virus reactivationhepatitis B virus recurrenceTransplantation

Identifiers

PMID29491759
PMCPMC5824593
OpenAlexW2886980931

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.